BEDFORD, Mass.--(BUSINESS WIRE)--Mar. 2, 2016--
Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company
focused on the development and commercialization of innovative therapies
for diseases and conditions of the eye, today announced that it will
report financial results for the fourth quarter and full year ended
December 31, 2015, on Thursday, March 10, 2016. Following distribution
of the earnings release via wire services, the Ocular management team
will host a live conference call and webcast at 8:00 a.m. Eastern Time
to review the Company’s financial results and provide a business update.
The live webcast can be accessed by visiting the investor section of
Ocular’s website at investors.ocutx.com.
Please connect to the Company's website at least 15 minutes prior to the
live webcast to ensure adequate time for any software download that may
be needed to access the webcast. Alternatively, please call 844-464-3934
(U.S.) or 765-507-2620 (International) to listen to the conference call.
The conference ID number for the live call will be 60154048. An archive
of the webcast will be available until March 24, 2016 on the company’s
website.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. (NASDAQ: OCUL) is a biopharmaceutical company
focused on the development and commercialization of innovative therapies
for diseases and conditions of the eye using its proprietary hydrogel
platform technology. Ocular Therapeutix's lead product candidate,
DEXTENZA™, is in Phase 3 clinical development for post-surgical ocular
inflammation and pain and allergic conjunctivitis, and in Phase 2
clinical development for inflammatory dry eye disease. An NDA for the
post-operative ocular pain indication has been accepted by the FDA with
a PDUFA date of July 24, 2016. A third Phase 3 clinical trial is being
conducted for post-operative ocular inflammation and pain. For glaucoma
and ocular hypertension, OTX-TP (sustained release travoprost)
intracanalicular depot, has completed a Phase 2b clinical trial, and
plans to commence the first of two planned Phase 3 clinical trials in
the third quarter of 2016. Ocular Therapeutix is also evaluating
sustained-release injectable anti-VEGF drug depots for back-of-the-eye
diseases. Ocular Therapeutix's first product, ReSure® Sealant, is
FDA-approved to seal corneal incisions following cataract surgery.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160302006157/en/
Source: Ocular Therapeutix, Inc.
Investors
Ocular Therapeutix, Inc.
Brad Smith
Chief
Financial Officer
bsmith@ocutx.com
or
Burns
McClellan on behalf of Ocular Therapeutix
Steve Klass, 212-213-0006
sklass@burnsmc.com
or
Media
Ocular
Therapeutix, Inc.
Scott Corning
Vice President of Sales and
Marketing
scorning@ocutx.com
